A Study of the Effects of Tamoxifen in the Frail Elderly: Difficulties Encountered in Nursing Home Research
- 30 June 1997
- journal article
- Published by Taylor & Francis in Women & Health
- Vol. 25 (1) , 37-51
- https://doi.org/10.1300/j013v25n01_03
Abstract
This study was conducted in order to determine whether the effects of tamoxifen in elderly, frail nursing home residents are similar to those that have been previously reported for younger postmenopausal women. A chart review study. The Jewish Home and Hospital for Aged (JHHA), a subacute long-term care facility. One hundred fifty-eight women who had been at the JHHA at any time since 1986. One hundred ten had a history of breast cancer; 43 of these had been treated with tamoxifen while at the JHHA (Group I), and 66 had not (Group II). The remaining 49 women had no history of breast cancer (Group III). Data were collected from the time of admission to the JHHA through August, 1994 on: chemistry profiles, bone fractures apparently not a consequence of metastasis, gynecological parameters, and thromboemboli. The lack of pre-admission clinical information presented problems regarding research design and the interpretation of our findings. Nevertheless, compared to women who had not been treated with tamoxifen, treated women had a significantly elevated incidence of vaginal discharge (P = 0.01) and a lower prevalence of elevated total cholesterol (P = 0.04). Although not statistically significant, they also had decreased levels of low density lipoprotein cholesterol and an increased incidence of thromboemboli and bone fractures. While some of the effects of tamoxifen in elderly, frail women are similar to those observed in younger, postmenopausal women, others may be different. Our results suggest a need for further innovative studies that focus on the consequences of tamoxifen treatment in the elderly, frail population.Keywords
This publication has 44 references indexed in Scilit:
- Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women After 5 Years of TreatmentJNCI Journal of the National Cancer Institute, 1994
- Ultrasonography surveillance of endometrium in breast cancer patients on adjuvant tamoxifenThe Lancet, 1994
- Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapyClinica Chimica Acta; International Journal of Clinical Chemistry, 1993
- Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death.Journal of Clinical Oncology, 1993
- Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast CancerNew England Journal of Medicine, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal WomenAnnals of Internal Medicine, 1991
- Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer—Preliminary reportGynecologic Oncology, 1991
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- PELVIC IRRADIATION AND TAMOXIFEN AS RISK FACTORS FOR CARCINOMA OF CORPUS UTERIThe Lancet, 1988